|11.77||-0.2300||-1.92%||Vol 689.97K||1Y Perf 271.61%|
|Apr 22nd, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||20.33||Analyst Rating||Strong Buy 1.00|
|Potential %||72.73||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||33/33/33||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-98/-98/-98||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-98/-98/-98||Income Ranking||— -|
|Market Cap||824.26M||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||34.00||Earnings Date||6th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||-0.12|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||837.60K|
|Avg. Monthly Volume||1.19M|
|Avg. Quarterly Volume||4.17M|
Anavex Life Sciences Corp. (NASDAQ: AVXL) stock closed at 11.77 per share at the end of the most recent trading day (a -1.92% change compared to the prior day closing price) with a volume of 690.65K shares and market capitalization of 824.26M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 20 people. Anavex Life Sciences Corp. CEO is Christopher U. Missling.
The one-year performance of Anavex Life Sciences Corp. stock is 271.61%, while year-to-date (YTD) performance is 117.96%. AVXL stock has a five-year performance of 124.62%. Its 52-week range is between 3.05 and 28.7, which gives AVXL stock a 52-week price range ratio of 34.00%
Anavex Life Sciences Corp. currently has a PE ratio of -26.20, a price-to-book (PB) ratio of 17.85, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -62.21%, a ROC of -76.23% and a ROE of -73.88%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Anavex Life Sciences Corp., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. Anavex Life Sciences Corp.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Anavex Life Sciences Corp. is Strong Buy (1), with a target price of $20.33, which is +72.73% compared to the current price. The earnings rating for Anavex Life Sciences Corp. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Anavex Life Sciences Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Anavex Life Sciences Corp. has a Neutral technical analysis rating based on Technical Indicators (ADX : 41.61, ATR14 : 1.25, CCI20 : -100.58, Chaikin Money Flow : -0.06, MACD : 0.21, Money Flow Index : 19.20, ROC : -22.00, RSI : 40.33, STOCH (14,3) : 16.77, STOCH RSI : 0.53, UO : 40.31, Williams %R : -83.23), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Anavex Life Sciences Corp. in the last 12-months were: Elliot Favus (Option Excercise at a value of $445 390), Elliot Favus (Sold 145 500 shares of value $1 841 855 ), Peter Donhauser (Buy at a value of $14 760)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.